Blau Farmacêutica: Record biotech investment and margin gains offset revenue dip; outlook for 2026 is strong

About this update from Blau Farmaceutica Sa

2025 saw strategic divestment, record investments in biotech, and improved margins despite a 3% revenue drop. Net income rose 39%, and new launches plus expanded capacity set the stage for stronger, less volatile growth in 2026.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Blau Farmaceutica Sa